Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx Limited filings document an operating epigenetics diagnostics company with public-company disclosures centered on Nu.Q® assays, capital structure and exchange compliance. Recent 8-K reports and proxy materials cover shareholder votes on common-stock issuance capacity and reverse-stock-split authority, the effectiveness of a one-for-twenty reverse split, and amendments to the company’s certificate of incorporation.
The filing record also includes material-event reports on NYSE American continued-listing standards, annual financial-result updates, unregistered sales of equity securities, convertible-note share settlements, private placements and warrants. These documents describe governance approvals, security-holder rights, financing mechanics, listing-compliance matters and operating updates for Volition’s diagnostics and monitoring business.
VolitionRx Ltd. President and CEO Cameron John Reynolds reported an award of 74,700 shares of common stock at $0.00 per share, following the vesting of restricted stock units (RSUs) tied to performance goals. These RSUs come from a March 17, 2025 grant of 249,000 RSUs under the company’s 2024 Stock Incentive Plan, where only a portion vested after certain corporate performance goals were achieved. The vested RSUs are subject to a three-year time-based schedule, with 24,900 units scheduled to vest on each of March 17, 2026, 2027 and 2028, delivering an equal number of common shares upon settlement. After this transaction, Reynolds directly holds 2,629,547 VolitionRx common shares, with additional indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.
VolitionRx Ltd director Alan Colman reported receiving 12,000 shares of common stock on January 22, 2026, coded as an acquisition at a price of $0 per share. Following this transaction, he beneficially owned 257,364 shares of VolitionRx common stock in direct ownership.
The filing explains that on March 17, 2025, he had been granted 40,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Performance conditions were satisfied for 12,000 RSUs, while the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd. director Timothy I. Still reported the acquisition of 90,000 shares of common stock on January 22, 2026, shown at a price of $0 per share, bringing his directly held stake to 1,625,458 shares. This reflects the vesting of performance-based restricted stock units awarded under the company’s 2024 Stock Incentive Plan.
The footnote explains that on March 17, 2025, Still received 300,000 RSUs tied to corporate performance goals and time-based vesting. Only the performance goals for 90,000 RSUs were met; the remaining 210,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The 90,000 RSUs that satisfied performance conditions are scheduled to vest in three equal installments of 30,000 units on March 17, 2026, 2027 and 2028, after which an equivalent number of common shares will be delivered.
VolitionRx Ltd's Group Chief Marketing Officer, Ann-Louise Batchelor, reported the acquisition of 33,900 shares of common stock on January 22, 2026 at a price of $0 per share, reflecting vesting of restricted stock units (RSUs) granted under the company’s 2024 Stock Incentive Plan. She now beneficially owns 182,072 common shares directly and 29,406 shares indirectly through her spouse.
The RSUs were part of a 113,000-unit award granted on March 17, 2025, tied to corporate performance goals and time-based vesting. Performance goals were met for 33,900 RSUs, while the remaining 79,100 RSUs were cancelled after targets were not achieved by June 30, 2025 and January 22, 2026.
VolitionRx Ltd.'s Chief Financial Officer, Terig Hughes, reported an acquisition of 49,200 shares of common stock on January 22, 2026, at a price of $0 per share. This reflects the vesting of part of a prior award of 164,000 restricted stock units (RSUs) granted on March 17, 2025 under the company’s 2024 Stock Incentive Plan.
Certain corporate performance goals were achieved, causing rights with respect to 49,200 RSUs to vest. These RSUs are subject to a three-year time-based vesting schedule in equal installments of 16,400 units on each of March 17, 2026, 2027 and 2028, after which shares are delivered upon settlement. Rights relating to the remaining 114,800 RSUs from the original grant did not vest and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd director Phillip Barnes reported acquiring 12,000 shares of common stock on January 22, 2026 at a price of $0, increasing his direct holdings to 67,368 shares. These shares relate to a grant of 40,000 restricted stock units (RSUs) awarded on March 17, 2025 under the company’s 2024 Stock Incentive Plan.
The RSUs were tied to corporate performance goals and time-based vesting. Only the targets for 12,000 RSUs were achieved; the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested portion is scheduled to vest over three years in equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each RSU that ultimately vests.
VolitionRx Ltd CEO Salvatore Thomas Butera reported an equity award related to restricted stock units (RSUs). On March 17, 2025 he was granted 178,000 RSUs under the company’s 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Certain performance goals were achieved, causing 53,400 RSUs to vest, which are reported as an acquisition of 53,400 shares of common stock at a price of $0 on January 22, 2026.
The 53,400 vested RSUs are subject to a 3‑year time-based schedule, vesting in three equal installments of 17,800 units on each of March 17, 2026, March 17, 2027 and March 17, 2028, after which shares of common stock will be delivered upon settlement. Following this transaction, Butera directly owns 375,203 shares of common stock and jointly owns an additional 99,350 shares with his spouse. The rights to the remaining 124,600 RSUs from the original grant did not vest and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd. officer Rodney Gerard Rootsaert reported an equity award tied to restricted stock units (RSUs). On January 22, 2026, he acquired 28,200 shares of common stock at a price of $0, reflecting vesting tied to a prior grant of 94,000 RSUs under the company’s 2024 Stock Incentive Plan. Certain performance goals were achieved, causing rights to 28,200 RSUs to vest, while rights to the remaining 65,800 RSUs were cancelled on June 30, 2025 and January 22, 2026.
The vested RSUs are also subject to a three-year time-based vesting schedule in equal installments of 9,400 units on March 17, 2026, 2027 and 2028, after which shares are delivered upon settlement. Following the reported transaction, Rootsaert directly owned 165,458 shares of VolitionRx common stock and indirectly owned 1,007,718 shares through Concord International, Inc., where he is a controlling director and shares voting and dispositive control.
VolitionRx Ltd's chief scientific officer, Jacob Vincent Micallef, reported the acquisition of 35,400 shares of common stock on January 22, 2026. These shares relate to restricted stock units granted on March 17, 2025 under the company’s 2024 Stock Incentive Plan, where certain corporate performance goals were achieved, allowing 35,400 RSUs to vest. The RSUs are subject to a three-year time-based schedule, vesting in three equal installments of 11,800 units on March 17, 2026, 2027, and 2028, after which an equal number of common shares will be delivered. Following this award, Micallef beneficially owns 428,489 shares directly, plus 55,000 shares indirectly via his spouse and 38,113 shares indirectly through Borlaug Limited, where he serves as a controlling director with voting and dispositive control.
VolitionRX Ltd GC Nicholas Plummer reported an equity award tied to performance-based RSUs. On January 22, 2026, he acquired 44,700 shares of common stock at $0 per share, increasing his directly held stake to 238,784 shares.
The shares relate to a grant of 149,000 restricted stock units (RSUs) made on March 17, 2025 under the company’s 2024 Stock Incentive Plan. Certain corporate performance goals through June 30, 2025 and December 31, 2025 were achieved, causing rights to the 44,700 RSUs to vest, while the remaining 104,300 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs are also subject to a three-year time-based vesting schedule, vesting in three equal installments of 14,900 units on each of March 17, 2026, 2027 and 2028, after which they settle into common shares.